M&A / Deals Biogen pens $1bn deal to buy immunology biotech RayThera PharmaphorumBiogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.Immunology & InflammationRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion. Immunology & Inflammation Read full story Post navigation Previous: Previous PostNext: LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026